Promise without practice — charting the path forward for bladder cancer biomarkers

IF 12.1 1区 医学 Q1 UROLOGY & NEPHROLOGY
Marie-Pier St-Laurent, Peter C. Black
{"title":"Promise without practice — charting the path forward for bladder cancer biomarkers","authors":"Marie-Pier St-Laurent, Peter C. Black","doi":"10.1038/s41585-025-01064-0","DOIUrl":null,"url":null,"abstract":"Bladder cancer is a biologically heterogeneous disease, and ongoing efforts in biomarker research aim to support personalized treatment approaches. Circulating tumour DNA is approaching clinical integration through prospective trials, whereas other markers remain investigational owing to technical limitations, inconsistent findings and lack of validation. Rigorous biomarker-driven trials and cost-effectiveness studies are needed to enable the integration of molecular tools into routine practice. Biomarkers might ultimately lead to rational treatment de-escalation or escalation, improving outcomes while minimizing harm and cost.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"11 1","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41585-025-01064-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Bladder cancer is a biologically heterogeneous disease, and ongoing efforts in biomarker research aim to support personalized treatment approaches. Circulating tumour DNA is approaching clinical integration through prospective trials, whereas other markers remain investigational owing to technical limitations, inconsistent findings and lack of validation. Rigorous biomarker-driven trials and cost-effectiveness studies are needed to enable the integration of molecular tools into routine practice. Biomarkers might ultimately lead to rational treatment de-escalation or escalation, improving outcomes while minimizing harm and cost.
没有实践的承诺-绘制膀胱癌生物标志物的前进道路
膀胱癌是一种生物学异质性疾病,生物标志物研究的持续努力旨在支持个性化治疗方法。通过前瞻性试验,循环肿瘤DNA正在接近临床整合,而由于技术限制、不一致的发现和缺乏验证,其他标记仍处于研究阶段。需要严格的生物标志物驱动试验和成本效益研究,才能将分子工具整合到常规实践中。生物标志物可能最终导致合理的治疗降级或升级,改善结果,同时最大限度地减少伤害和成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Reviews Urology
Nature Reviews Urology 医学-泌尿学与肾脏学
CiteScore
12.50
自引率
2.60%
发文量
123
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信